Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;66(2):183-8.
doi: 10.1097/FJC.0000000000000261.

Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region

Affiliations
Free PMC article

Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region

Sarah E OʼBrien et al. J Cardiovasc Pharmacol. .
Free PMC article

Abstract

Genetic variants within the BUD13-APOA5 gene region are known to be associated with high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. Recent studies suggest that single nucleotide polymorphisms (SNPs) within this region affect HDL-C response to statin-fibrate combination therapy and low-density lipoprotein cholesterol (LDL-C) response to statin therapy. We hypothesized that SNPs within the BUD13-APOA5 region are associated with TG, HDL-C, and LDL-C response to statin therapy. We examined 1520 observations for 1086 patients from the Personalized Medicine Research Project, a large biorepository at the Marshfield Clinic Research Foundation, who had received statin therapy and been previously genotyped for polymorphisms in the 11q23 chromosomal region. A significant differential response to statin therapy was observed for 3 SNPs. The minor allele at rs11605293 significantly attenuated TG-lowering response to pravastatin (P = 0.000159), whereas the minor allele at rs12806755 was associated with a similar response to lovastatin (P = 0.000192). Genotypes at rs947990 significantly attenuated LDL-C reduction to atorvastatin therapy (P = 0.000668) with some patients with the minor allele having LDL-C increase after therapy. No SNPs within the BUD13-APOA5 region were associated with a significant effect on HDL-C reduction in response to statin therapy. In conclusion, this study suggests that common SNPs within the BUD13-APOA5 can affect TG and LDL-C response to statin therapy in a North American population.

Conflict of interest statement

The authors report no conflict of interest.

Figures

Figure 1
Figure 1. Selection of Subjects
Figure 2
Figure 2
(A) % Change in TG by rs11605293 Genotype for Pravastatin Treatment. (B) % Change in TG by rs12806755 Genotype for Lovastatin Treatment. (C) % Change in LDL by rs947990 Genotype for Atorvastatin Treatment. (adjusted for age, BMI, gender, race, smoking, diabetes2, and time on drug.)

Similar articles

See all similar articles

Cited by 5 articles

Publication types

Feedback